Reports Q3 revenue $2.17M, consensus $820,800. “In the third quarter, we focused on developing BDC-4182, the first next-generation Boltbody ISAC in our pipeline. We are actively enrolling patients with gastric and gastroesophageal cancer in the Phase 1 dose-escalation study. We now look forward to presenting initial data in the third quarter of 2026,” said Willie Quinn, President and Chief Executive Officer. “With our cash runway now expected to extend into 2027, we are in a financial position to create long-term value for our shareholders and fulfill our mission of bringing new treatment options to patients with cancer.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BOLT:
- Bolt Biotherapeutics’ Pioneering Study on BDC-4182: A New Hope for Cancer Treatment
- Buy Rating for Bolt Biotherapeutics: Innovative Cancer Treatment Approach and Strategic Financial Management
- Bolt Biotherapeutics assumed with a Buy at H.C. Wainwright
- Bolt Biotherapeutics Announces Major Restructuring Plan
- Bolt Biotherapeutics to reduce workforce by 50%, gives update on BDC-4182 study